Medtronic Defends Endeavor DES Late Loss, Questions Clinical Relevance
This article was originally published in The Gray Sheet
Executive Summary
The relatively high rates of late lumen loss in Medtronic's ENDEAVOR-I drug-eluting stent trial can be traced to the large reference vessel size of the study subjects, according to Harvard Medical School's Richard Kuntz, MD